US FDA refuses to approve first MDMA-based treatment for PTSD
The U.S. FDA has refused to approve a mind-altering MDMA-based therapy for patients with post-traumatic stress disorder, saying it cannot be approved based on the data submitted, developer Lykos Therapeutics said.
BELIEBTE BEITRÄGE
Putin may discuss Ukraine peace deal with Trump
November 22, 2024
Spain’s vice-president Ribera blames floods on climate change
November 22, 2024
Storm lashes northwestern US, killing two people
November 22, 2024
Iceland volcano erupts for tenth time in three years
November 22, 2024
LIVEÜBERTRAGUNG